glp 1 and antidepressants Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical clinical evidence Insights into a possible role

AKI was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) consensus serum creatinine criteria as either an increase in serum creatinine of 0.3 mg/dL (26.5 mol/L) within 48 hours or an increase to 1.5 times baseline within the preceding 7 days ( Cardiovascular outcomes were evaluated using a prespecified composite endpoint

Researchers realized that enhancing the body's own GLP-1 system could offer safer, more physiological diabetes control than insulin injections or oral medications that forced the pancreas to work harder

Losing weight is not so easy

Cardiovasc Diabetol 21 , 242 (2022)

Rising prevalence of diabetes and obesity, advancement in drug delivery technologies, and growing focus on preventive healthcare and personalized medicine are major key factors driving the market revenue growth of the GLP-1 Receptor Agonist market

1 Results showed that if all patients stayed on treatment, people taking Wegovy pill once-daily along with a reduced calorie diet and exercise achieved an average weight loss of about 17% (16.6%) versus about 3% (2.7%) with placebo